Lexeo Appoints New COO and VP of Cardiology Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 27 2026
0mins
Should l Buy LXEO?
In addition to Dr. Bhalla's appointment, Lexeo announced the following updates: Jose Manuel Otero, PhD has been appointed COO, transitioning from his role as Chief Technical Officer, effective immediately. Hayes Dansky, MD has joined Lexeo as Vice President, Late-Stage Cardiology Development. He most recently served as Vice President of Innovation at Novo Nordisk's Bio Innovation Hub, supporting cardiometabolic disease initiatives, and previously served as Head of Clinical Development at Roivant and Sumitovant. Greg Aubert, MD, PhD has been named Vice President, Early-Stage Cardiology Development and Translational Science. He previously served as the Director of the Clinical and Translational Research Division at the Loyola University Cardiovascular Research Institute, where he founded the institution's Cardiovascular Genetics Clinic, and later led late-stage clinical trials at CSL Vifor.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LXEO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LXEO
Wall Street analysts forecast LXEO stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.200
Low
13.00
Averages
20.29
High
30.00
Current: 7.200
Low
13.00
Averages
20.29
High
30.00
About LXEO
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lexeo Therapeutics Announces Investor Conference Schedule
- Investor Conference Schedule: Lexeo Therapeutics will participate in two significant investor conferences in February 2026, namely the Guggenheim Emerging Outlook: Biotech Summit and the Oppenheimer 36th Annual Healthcare Life Sciences Conference, showcasing its innovative advancements in cardiovascular disease treatment.
- Live Webcast and Replay: Both events will be webcast live on the company's investor section of the website, ensuring that investors can access the latest information in real-time, with replays available post-event to enhance engagement and transparency with stakeholders.
- Company Overview: Lexeo Therapeutics is a New York City-based clinical-stage genetic medicine company focused on reshaping cardiovascular disease treatment through pioneering science, dedicated to developing therapeutic candidates targeting the genetic causes of conditions to meet high unmet medical needs.
- Therapeutic Candidates: The company is advancing multiple therapeutic candidates, including LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for plakophilin-2 arrhythmogenic cardiomyopathy, demonstrating its potential in addressing diseases with significant unmet needs.
See More
Lexeo Therapeutics Announces Key Senior Leadership Appointments
- Executive Appointments: Lexeo Therapeutics appoints Dr. Narinder Bhalla as Chief Medical Officer, leveraging over 20 years of experience in cardiovascular medicine and biopharma to drive innovation and development in cardiovascular disease treatments.
- Strategic Partnership Update: The collaboration with Perceptive Xontogeny Venture Funds and venBio Partners aims to develop therapies for genetic cardiac diseases using a novel non-viral RNA platform, reinforcing Lexeo's leadership in gene therapy.
- Operational Efficiency Boost: Dr. José Manuel Otero has been appointed Chief Operating Officer, focusing on enhancing Lexeo's operational efficiency and clinical supply capabilities while ensuring a smooth transition of manufacturing platforms under high regulatory standards.
- R&D Team Expansion: Newly appointed Dr. Hayes Dansky and Dr. Greg Aubert will lead late-stage and early-stage cardiology development, respectively, and their extensive R&D experience is expected to accelerate Lexeo's clinical progress in cardiovascular gene therapies.
See More
Telsey Raises Five Below Inc Price Target to $240
- Price Target Increase: Telsey Advisory Group raised the price target for Five Below Inc from $195 to $240, with analyst Joseph Feldman maintaining an Outperform rating, indicating strong confidence in the company's future growth prospects.
- Rating Maintained: Despite HC Wainwright & Co. cutting Lexeo Therapeutics Inc's price target from $13 to $10, analyst Mitchell S. Kapoor maintained a Buy rating, reflecting optimism about its long-term potential.
- Price Target Cut: Needham reduced the price target for Apellis Pharmaceuticals Inc from $29 to $28, yet analyst Joseph Stringer upheld a Buy rating, demonstrating ongoing confidence in the company's fundamentals.
- Rating Downgrade: Daiwa Capital lowered PayPal Holdings Inc's price target from $77 to $61 and downgraded the rating from Outperform to Neutral, indicating a cautious outlook on its future performance.
See More
U.S. Stocks Mixed; Day One Biopharmaceuticals Shares Surge 20%
- Mixed Market Performance: U.S. stocks exhibited mixed results on Monday, with the Nasdaq Composite gaining over 50 points and rising 0.29%, while the Dow Jones fell 0.19% to 49,411.94, indicating market volatility and investor caution.
- Biopharma Surge: Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares surged 20% to $10.77 after reporting a projected 2025 OJEMDA net product revenue of $155.4 million, a 172% year-over-year increase, highlighting strong market demand and growth potential.
- FDA Response Impact: Atara Biotherapeutics Inc (NASDAQ:ATRA) shares plummeted 53% to $6.41 following a Complete Response Letter from the FDA citing concerns over clinical trial adequacy, raising investor worries about the company's future prospects.
- Sector Sentiment Fluctuations: Financial stocks dipped by 1.1% while consumer staples rose by 1%, reflecting differing investor confidence across sectors, which may influence future investment strategies and market trends.
See More
IBM and LXEO Options Show Significant Volume Surge
- IBM Options Volume: As of now, IBM options have reached a trading volume of 15,715 contracts, representing approximately 42.3% of the average daily trading volume of 3.7 million shares over the past month, indicating a significant increase in market interest in the stock.
- High-Frequency Contracts: Within IBM, the $312.50 strike call option has seen 932 contracts traded today, involving about 93,200 shares, reflecting investor expectations for future price appreciation.
- LXEO Options Activity: LXEO's options trading volume stands at 6,208 contracts, accounting for approximately 42% of its average daily trading volume of 1.5 million shares over the past month, suggesting sustained market interest in the company.
- Key Contract Insights: For LXEO, the $11 strike call option has traded 2,891 contracts today, representing around 289,100 shares, showcasing investor optimism regarding its future performance.
See More
Lexeo Therapeutics Partners with J&J to Advance Gene Therapy for Cardiovascular Diseases
- Research Collaboration Initiated: Lexeo Therapeutics has announced a partnership with Johnson & Johnson to focus on localized AAV gene therapy delivery to the heart using Impella heart pump technology, aiming to enhance the efficacy and safety profile for genetically mediated cardiovascular diseases.
- Innovative Technology Application: This collaboration will explore advanced routes of administration, which not only aids in advancing cardiac genetic medicine but also potentially offers more effective treatment options for cardiovascular disease patients, thereby improving their quality of life.
- Positive Market Reaction: Following the announcement, Lexeo's stock price rose by 1.50% to $10.17 in pre-market trading on Nasdaq, reflecting investor optimism regarding the prospects of this collaboration.
- Strategic Implications: CEO Nolan Townsend emphasized that this partnership combines Lexeo's leadership in cardiac genetic medicine with Impella's world-class technology, marking a significant advancement in the next generation of targeted genetic medicines for cardiovascular diseases.
See More
Lexeo Therapeutics Announces Investor Conference Schedule
- Investor Conference Schedule: Lexeo Therapeutics will participate in two significant investor conferences in February 2026, namely the Guggenheim Emerging Outlook: Biotech Summit and the Oppenheimer 36th Annual Healthcare Life Sciences Conference, showcasing its innovative advancements in cardiovascular disease treatment.
- Live Webcast and Replay: Both events will be webcast live on the company's investor section of the website, ensuring that investors can access the latest information in real-time, with replays available post-event to enhance engagement and transparency with stakeholders.
- Company Overview: Lexeo Therapeutics is a New York City-based clinical-stage genetic medicine company focused on reshaping cardiovascular disease treatment through pioneering science, dedicated to developing therapeutic candidates targeting the genetic causes of conditions to meet high unmet medical needs.
- Therapeutic Candidates: The company is advancing multiple therapeutic candidates, including LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for plakophilin-2 arrhythmogenic cardiomyopathy, demonstrating its potential in addressing diseases with significant unmet needs.
See More
Lexeo Therapeutics Announces Key Senior Leadership Appointments
- Executive Appointments: Lexeo Therapeutics appoints Dr. Narinder Bhalla as Chief Medical Officer, leveraging over 20 years of experience in cardiovascular medicine and biopharma to drive innovation and development in cardiovascular disease treatments.
- Strategic Partnership Update: The collaboration with Perceptive Xontogeny Venture Funds and venBio Partners aims to develop therapies for genetic cardiac diseases using a novel non-viral RNA platform, reinforcing Lexeo's leadership in gene therapy.
- Operational Efficiency Boost: Dr. José Manuel Otero has been appointed Chief Operating Officer, focusing on enhancing Lexeo's operational efficiency and clinical supply capabilities while ensuring a smooth transition of manufacturing platforms under high regulatory standards.
- R&D Team Expansion: Newly appointed Dr. Hayes Dansky and Dr. Greg Aubert will lead late-stage and early-stage cardiology development, respectively, and their extensive R&D experience is expected to accelerate Lexeo's clinical progress in cardiovascular gene therapies.
See More
Telsey Raises Five Below Inc Price Target to $240
- Price Target Increase: Telsey Advisory Group raised the price target for Five Below Inc from $195 to $240, with analyst Joseph Feldman maintaining an Outperform rating, indicating strong confidence in the company's future growth prospects.
- Rating Maintained: Despite HC Wainwright & Co. cutting Lexeo Therapeutics Inc's price target from $13 to $10, analyst Mitchell S. Kapoor maintained a Buy rating, reflecting optimism about its long-term potential.
- Price Target Cut: Needham reduced the price target for Apellis Pharmaceuticals Inc from $29 to $28, yet analyst Joseph Stringer upheld a Buy rating, demonstrating ongoing confidence in the company's fundamentals.
- Rating Downgrade: Daiwa Capital lowered PayPal Holdings Inc's price target from $77 to $61 and downgraded the rating from Outperform to Neutral, indicating a cautious outlook on its future performance.
See More
U.S. Stocks Mixed; Day One Biopharmaceuticals Shares Surge 20%
- Mixed Market Performance: U.S. stocks exhibited mixed results on Monday, with the Nasdaq Composite gaining over 50 points and rising 0.29%, while the Dow Jones fell 0.19% to 49,411.94, indicating market volatility and investor caution.
- Biopharma Surge: Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares surged 20% to $10.77 after reporting a projected 2025 OJEMDA net product revenue of $155.4 million, a 172% year-over-year increase, highlighting strong market demand and growth potential.
- FDA Response Impact: Atara Biotherapeutics Inc (NASDAQ:ATRA) shares plummeted 53% to $6.41 following a Complete Response Letter from the FDA citing concerns over clinical trial adequacy, raising investor worries about the company's future prospects.
- Sector Sentiment Fluctuations: Financial stocks dipped by 1.1% while consumer staples rose by 1%, reflecting differing investor confidence across sectors, which may influence future investment strategies and market trends.
See More
IBM and LXEO Options Show Significant Volume Surge
- IBM Options Volume: As of now, IBM options have reached a trading volume of 15,715 contracts, representing approximately 42.3% of the average daily trading volume of 3.7 million shares over the past month, indicating a significant increase in market interest in the stock.
- High-Frequency Contracts: Within IBM, the $312.50 strike call option has seen 932 contracts traded today, involving about 93,200 shares, reflecting investor expectations for future price appreciation.
- LXEO Options Activity: LXEO's options trading volume stands at 6,208 contracts, accounting for approximately 42% of its average daily trading volume of 1.5 million shares over the past month, suggesting sustained market interest in the company.
- Key Contract Insights: For LXEO, the $11 strike call option has traded 2,891 contracts today, representing around 289,100 shares, showcasing investor optimism regarding its future performance.
See More
Lexeo Therapeutics Partners with J&J to Advance Gene Therapy for Cardiovascular Diseases
- Research Collaboration Initiated: Lexeo Therapeutics has announced a partnership with Johnson & Johnson to focus on localized AAV gene therapy delivery to the heart using Impella heart pump technology, aiming to enhance the efficacy and safety profile for genetically mediated cardiovascular diseases.
- Innovative Technology Application: This collaboration will explore advanced routes of administration, which not only aids in advancing cardiac genetic medicine but also potentially offers more effective treatment options for cardiovascular disease patients, thereby improving their quality of life.
- Positive Market Reaction: Following the announcement, Lexeo's stock price rose by 1.50% to $10.17 in pre-market trading on Nasdaq, reflecting investor optimism regarding the prospects of this collaboration.
- Strategic Implications: CEO Nolan Townsend emphasized that this partnership combines Lexeo's leadership in cardiac genetic medicine with Impella's world-class technology, marking a significant advancement in the next generation of targeted genetic medicines for cardiovascular diseases.
See More
